NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free FBLG Stock Alerts $7.93 -1.50 (-15.91%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$7.79▼$9.5950-Day Range$7.93▼$13.0652-Week Range$6.53▼$55.00Volume61,345 shsAverage Volume67,487 shsMarket Capitalization$258.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get FibroBiologics alerts: Email Address Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About FibroBiologics Stock (NASDAQ:FBLG)FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Read More FBLG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBLG Stock News HeadlinesApril 26, 2024 | msn.comFibroBiologics files to sell 1.8M unitsApril 25, 2024 | finance.yahoo.comFibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based SpheroidsMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 15, 2024 | finance.yahoo.comFibroBiologics, Inc. (FBLG)April 15, 2024 | finance.yahoo.comFibroBiologics, Inc. (FBLG) Interactive Stock Chart - Yahoo FinanceApril 12, 2024 | investing.comFibroBiologics secures Australian patent for cartilage repairApril 11, 2024 | finanznachrichten.deFibrobiologics, Inc.: FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent OfficeApril 11, 2024 | globenewswire.comFibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent OfficeMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 6, 2024 | uk.investing.comFibroBiologics reports promising wound healing studyApril 4, 2024 | globenewswire.comFibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USAMarch 28, 2024 | globenewswire.comFibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of LupusMarch 19, 2024 | seekingalpha.comFibroBiologics reports encouraging early data for diabetes cell therapyMarch 19, 2024 | prnewswire.comFibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes TreatmentMarch 13, 2024 | prnewswire.comFibroBiologics to Present at Advanced Wound Care Summit USAMarch 6, 2024 | morningstar.comFibroBiologics Inc FBLGMarch 6, 2024 | prnewswire.comFibroBiologics Appoints Ruben A. Garcia as General CounselFebruary 29, 2024 | prnewswire.comFibroBiologics Files 2023 Form 10-K Annual ReportFebruary 20, 2024 | prnewswire.comFibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) ForumFebruary 8, 2024 | finance.yahoo.comFibroBiologics Announces Three United States Patents for Fibroblast TechnologyFebruary 7, 2024 | msn.comFibroBiologics Broadens IP Reach with Japanese PatentsSee More Headlines Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CUSIPN/A CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book198.25Miscellaneous Outstanding Shares32,630,000Free FloatN/AMarket Cap$258.76 million OptionableN/A BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Peter O'Heeron (Age 60)Founder, Chairman & CEO Comp: $950.72kMr. Mark C. Andersen C.F.A. (Age 52)CPA, M.B.A., Chief Financial Officer Comp: $461.88kDr. Hamid Khoja Ph.D. (Age 54)Chief Scientific Officer Comp: $423.12kMr. Ruben A. GarciaGeneral CounselKey CompetitorsOrganogenesisNASDAQ:ORGOErascaNASDAQ:ERASAtea PharmaceuticalsNASDAQ:AVIRSilverback TherapeuticsNASDAQ:SBTXNeoleukin TherapeuticsNASDAQ:NLTXView All Competitors FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed in 2024? FibroBiologics' stock was trading at $17.75 on January 1st, 2024. Since then, FBLG shares have decreased by 55.3% and is now trading at $7.93. View the best growth stocks for 2024 here. When did FibroBiologics IPO? FibroBiologics (FBLG) raised $144 million in an initial public offering (IPO) on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share. When does the company's lock-up period expire? FibroBiologics' lock-up period expires on Monday, July 29th. FibroBiologics had issued 4,806,226 shares in its IPO on January 31st. The total size of the offering was $144,186,780 based on an initial share price of $30.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBLG) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
